Auh Jin ("어진" in Korean) is Vice Chairman and CEO of Ahngook Pharmaceutical, sharing the leadership with co-CEO Park In-cheol.
He is focused on enhancing the company’s drug development capabilities.
Born on March 30, 1964, Auh Jin is the eldest son among two sons and three daughters of former Honorary Chairman Auh Jun-seon and Im Young-gyun.
He graduated from Kyungseong High School in Seoul and earned a degree in economics from Korea University. He later completed an MBA program at the University of Notre Dame in the United States.
Auh began his career at Daishin Securities, then moved to Ahngook Pharmaceutical, the company founded by his father. There, he held roles including head of planning and director of general affairs before becoming CEO in 1998.
In 2022, he stepped down from management after being indicted for charges involving rebates and illegal clinical trials.
He later returned to the company as Vice Chairman and inside director, and in 2024, he was reinstated as CEO, taking charge of new business ventures.
As a second-generation executive at Ahngook Pharmaceutical, he has worked at the company for more than 30 years, gaining extensive experience in the pharmaceutical and biotech industries.
Auh prefers focusing on internal operations rather than external activities and is committed to discovering new growth drivers and diversifying the company’s business portfolio.
He served a prison sentence for charges related to illegal clinical trials and offering rebates and was released in October 2024. This has raised ongoing concerns about “owner risk” for the company.
#AhngookPharmaceutical #AuhJin #KoreanPharmaceuticalIndustry #biotech #drugdevelopment #CEO #rebatelawsuit #illegaltrials #pharmaexecutive #ownerleadership